Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases and Their Primary Caregivers (CAREGIVERSPRO)
Pilot Study to Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases Including Persons Living With Mild Cognitive Impairment or Mild to Moderate Dementia and Their Primary Caregivers
Sponsor: Centre Hospitalier Intercommunal Elbeuf-Louviers-Val de Reuil
Listed as NCT03536975, this observational or N/A phase trial focuses on Cognitive Impairment, Mild and Dementia, Mild and remains completed. Sponsored by Centre Hospitalier Intercommunal Elbeuf-Louviers-Val de Reuil, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Apr 18, 2026 — Present [daily]
Completed
Phase: NA → None
-
Feb 2026 — Apr 2026 [monthly]
Completed NA
Status: Unknown → Completed
-
Sep 2025 — Feb 2026 [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Recruiting NA
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Our main goal is to test a web platform accessible by computers, smartphones and tablets, addressed specifically to caregivers and people with mild cognitive deterioration or mild to moderate dementia providing added value services based on social networks, adapted interventions, clinic strategies and gamification to improve the quality of life of caregivers and people living with dementia (dyads) and permitting to leave in the community as long as possible. To evaluate the platform effectiveness and impact in dementia type disease affected people and caregivers a randomized, controlled, parallel, longitudinal is proposed. The objective will be to assess during 18 months aspects related to health of individuals (general aspect of health, neuropsychological, daily living functionalities, quality of life, treatment adherence, comorbidities ...), social aspects (improving dyad relationship…) and economics (cost-effectiveness of platform utilization), as well as satisfaction degree and usability of platform.
Contact Information
- Centre Hospitalier Intercommunal Elbeuf-Louviers-Val de Reuil
- University Hospital, Rouen
For direct contact, visit the study record on ClinicalTrials.gov .